Loading data for ESLA — first visit, this takes a few seconds.
Estrella Immunopharma Inc... (ESLA)
NasdaqCM: ESLA
· Real-Time Price · USD
0.72
+0.00 (0.00%)
At close: Aug 18, 2026, 8:00 PM
Estrella Immunopharma Inc. (ESLA) Stock Price, Analysis & Data
0.00% (1D)
No data available
| Bid | 1.14 |
| Market Cap | 31.85M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.01M |
| Beta | n/a |
| EPS (ttm) | -0.24 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.29 |
| P/B (ttm) | -5.90 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 1.17 |
| Volume | 8,996 |
| Avg. Volume (20D) | 38,720 |
| Open | 0.74 |
| Previous Close | 0.72 |
| Day's Range | 0.72 - 0.74 |
| 52-Week Range | 0.68 - 3.15 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ESLA
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 14, 2021
Employees n/a
Stock Exchange NasdaqCM
Ticker Symbol ESLA
Website https://www.estrellabio.com
Financial Performance
In 2025, Estrella Immunopharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -13.06M, an increase of 78.67%.
Financial StatementsEarnings Surprise
Estrella Immunopharma has released their quarterly earnings on May 18, 2026:
